Odonate Therapeutics’ (NASDAQ:ODT) quiet period is set to expire on Tuesday, January 16th. Odonate Therapeutics had issued 6,250,000 shares in its IPO on December 7th. The total size of the offering was $150,000,000 based on an initial share price of $24.00. During Odonate Therapeutics’ quiet period, insiders and underwriters involved in the IPO are restricted from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the expiration of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.
A number of research analysts have recently commented on the company. Goldman Sachs Group assumed coverage on Odonate Therapeutics in a report on Tuesday, January 2nd. They set a “neutral” rating and a $27.00 price objective on the stock. Cowen assumed coverage on Odonate Therapeutics in a report on Tuesday, January 2nd. They set an “outperform” rating on the stock. Finally, Jefferies Group assumed coverage on Odonate Therapeutics in a report on Tuesday, January 2nd. They set a “buy” rating and a $40.00 price objective on the stock.
Odonate Therapeutics (NASDAQ:ODT) opened at $23.79 on Friday. The company has a market capitalization of $639.72 and a PE ratio of -33.51. Odonate Therapeutics has a fifty-two week low of $22.31 and a fifty-two week high of $25.36.
ILLEGAL ACTIVITY WARNING: This piece of content was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.com-unik.info/2018/01/13/odonate-therapeutics-incs-odt-quiet-period-to-expire-on-january-16th.html.
About Odonate Therapeutics
Odonate Therapeutics, Inc, formerly Odonate Therapeutics, LLC, is a pharmaceutical company. The Company is engaged in the development of therapeutics to improve and extend the lives of patients with cancer. It is focused on the development of tesetaxel, a novel chemotherapy agent. It has completed Phase-II studies in patients with metastatic breast cancer (MBC).
Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.